Last $11.35 USD
Change Today +0.01 / 0.09%
Volume 1.3M
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Open
$11.43
Previous Close
$11.34
Day High
$11.73
Day Low
$11.20
52 Week High
10/25/13 - $18.19
52 Week Low
08/1/14 - $10.28
Market Cap
975.1M
Average Volume 10 Days
646.3K
EPS TTM
$-0.69
Shares Outstanding
85.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the treatment of mesothelioma and ovarian cancer; BT-062 for multiple myeloma; SAR3419, which has completed Phase II clinical trials for the treatment of diffuse large B-cell lymphoma; SAR650984 that is in early clinical trials for the treatment of multiple myeloma; SAR566658 that is in Phase I clinical trials for treating CA6-positive solid tumors; and SAR408701 for solid tumors. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; and Sanofi. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

307 Employees
Last Reported Date: 08/28/14
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $502.6K
Chief Medical Officer and Vice President
Total Annual Compensation: $376.3K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $367.7K
Vice President, Secretary and General Counsel
Total Annual Compensation: $297.3K
Compensation as of Fiscal Year 2013.

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. announced that Dr. James J. O'Leary, Vice President and Chief Medical Officer of the company of his intention to leave the company's employ in mid-October 2014 for personal reasons. His responsibilities will be assumed by Dr. Charles Q. Morris, Executive Vice President and Chief Development Officer, to whom Dr. O'Leary currently reports.

ImmunoGen, Inc. Hires Sandra E. Poole as Senior Vice President of Technical Operations

ImmunoGen, Inc. announced the appointment of Sandra E. Poole as Senior Vice President, Technical Operations. Ms. Poole brings to ImmunoGen more than 25 years of experience related to the development and manufacturing of innovative biopharmaceuticals, most recently as the senior vice president of biologics manufacturing at Genzyme. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.

ImmunoGen, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:55 AM

ImmunoGen, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:55 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $11.35 USD +0.01

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €8.40 EUR +0.122
BioInvent International AB kr3.19 SEK 0.00
Genmab A/S kr237.80 DKK +4.00
MorphoSys AG €75.48 EUR +0.99
Seattle Genetics Inc $40.60 USD -0.55
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.3x
Price/Book 12.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.